Veyret, C.

patient treatment cancer tamoxifen breast breast cancer study survival buserelin group response disease metastatic breast cancer objective response rate value premenopausal effect agonist estradiol level disease progression progression-free survival plasma estradiol levels metastatic result difference plasma month therapy table receptor objective lhrh agonist goserelin chemotherapy tumor hormone pg /ml estrogen interval progression-free disease-free interval randomized remission cancer institute lhrh-a adjuvant premenopausal women status premenopausal patients 161 patients treatment groups trial progression p values 6 months klijn response rate oncology disease-free women number institute factor prognostic combined-treatment arm combination single-treatment arms adjuvant chemotherapy blamey rw department 2 years center netherland castration luteinizing objective response plasma estradiol european organization comparison